KRAS, a New Target for Precision Medicine in Colorectal Cancer?
Alice Boilève1,2,3, Cristina Smolenschi1,4, Aurélien Lambert5
1Gustave Roussy, Département de Médecine Oncologique, 94805 Villejuif, France.
Abstract:
Colorectal cancer (CRC) remains a leading cause of cancer-related mortality globally, with significant public health concerns. This review examines the landscape of KRAS inhibition in colorectal cancer (CRC), focusing on recent advances in therapeutic strategies targeting this oncogene. Historically deemed undruggable due to its complex structure and essential role in tumorigenesis, KRAS mutations are prevalent in CRC and are associated with poor prognosis. However, breakthroughs in drug development have led to the emergence of KRAS inhibitors as promising treatment options. This review discusses various classes of KRAS inhibitors, including covalent and non-covalent inhibitors, as well as combination therapies aimed at enhancing efficacy and overcoming resistance mechanisms. It highlights recent clinical trials evaluating the efficacy of KRAS inhibitors either as monotherapy or in combination with other agents, such as anti-EGFR antibodies. Despite challenges such as resistance mechanisms and tumor heterogeneity, the development of KRAS inhibitors represents a significant advance in CRC treatment and holds promise for improving patient outcomes in the future.
Insights
Targeting KRAS mutations in colorectal cancer (CRC) is advancing. New KRAS inhibitors show promise for improving outcomes in CRC patients, despite challenges like resistance.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Colorectal cancer (CRC) is a major global health concern, with KRAS mutations often linked to poor prognosis.
- KRAS oncogene has historically been challenging to target therapeutically due to its complex structure.
Purpose of the Study:
- To review recent advancements in KRAS inhibition strategies for colorectal cancer.
- To explore the efficacy and challenges of emerging KRAS inhibitors and combination therapies.
Main Methods:
- Literature review of recent studies and clinical trials on KRAS inhibitors in CRC.
- Analysis of different classes of KRAS inhibitors (covalent, non-covalent) and combination approaches.
Main Results:
- Emergence of KRAS inhibitors as viable therapeutic options for CRC.
- Clinical trials demonstrate potential efficacy of KRAS inhibitors, alone or with other agents like anti-EGFR antibodies.
Conclusions:
- KRAS inhibitors represent a significant therapeutic advance in colorectal cancer treatment.
- Ongoing research aims to overcome resistance mechanisms and tumor heterogeneity for improved patient outcomes.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...